Plain-English translation of NCT07855302 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called for children and young adults with severe lupus that started in childhood and hasn't responded well to standard medications. The treatment uses your own immune cells, which are modified in a laboratory to attack the B cells that contribute to lupus. You would receive chemotherapy to prepare your body, then a single infusion of these modified cells.
Standard lupus medications don't work well enough for some patients, leaving them with ongoing organ damage and poor quality of life. This trial is exploring whether this newer approach of using engineered immune cells might help patients whose disease remains active despite trying multiple existing treatments.
You likely qualify if…
You likely don't qualify if…
You would undergo chemotherapy to reduce your existing immune cells, then receive a single intravenous infusion of your modified cells. After that, the study team would monitor you closely for side effects and changes in your lupus symptoms, organ involvement, and blood tests for at least one year. You would have regular clinic visits and blood work to track how well the treatment is working and whether you can reduce other lupus medications.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
South Korea